title: Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters.
abstract: It is unclear whether karyotype aberrations that occur in regions uncovered by the standard fluorescence in situ hybridization (FISH) panel have prognostic relevance in chronic lymphocytic leukemia (CLL). We evaluated the significance of karyotypic aberrations in a learning cohort (LC; n = 64) and a validation cohort (VC; n = 84) of patients with chronic lymphocytic leukemia with "normal" FISH. An abnormal karyotype was found in 21.5% and 35.7% of cases in the LC and VC, respectively, and was associated with a lower immunophenotypic score (P = .030 in the LC, P = .035 in the VC), advanced stage (P = .040 in the VC), and need for treatment (P = .002 in the LC, P = < .0001 in the VC). The abnormal karyotype correlated with shorter time to first treatment and shorter survival in both the LC and the VC, representing the strongest prognostic parameter. In patients with chronic lymphocytic leukemia with normal FISH, karyotypic aberrations by conventional cytogenetics with novel mitogens identify a subset of cases with adverse prognostic features.
authors.affiliation: Section of Hematology, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy. rglgmt@unife.it
authors.forename: Gian Matteo
authors.initials: GM
authors.lastname: Rigolin
authors.forename: Francesca
authors.initials: F
authors.lastname: Cibien
authors.forename: Sara
authors.initials: S
authors.lastname: Martinelli
authors.forename: Luca
authors.initials: L
authors.lastname: Formigaro
authors.forename: Lara
authors.initials: L
authors.lastname: Rizzotto
authors.forename: Elisa
authors.initials: E
authors.lastname: Tammiso
authors.forename: Elena
authors.initials: E
authors.lastname: Saccenti
authors.forename: Antonella
authors.initials: A
authors.lastname: Bardi
authors.forename: Francesco
authors.initials: F
authors.lastname: Cavazzini
authors.forename: Maria
authors.initials: M
authors.lastname: Ciccone
authors.forename: Ilaria
authors.initials: I
authors.lastname: Nichele
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pizzolo
authors.forename: Francesco
authors.initials: F
authors.lastname: Zaja
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
authors.forename: Piero
authors.initials: P
authors.lastname: Galieni
authors.forename: Alessia
authors.initials: A
authors.lastname: Dalsass
authors.forename: Francesca
authors.initials: F
authors.lastname: Mestichelli
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Testa
authors.forename: Massimo
authors.initials: M
authors.lastname: Negrini
authors.forename: Antonio
authors.initials: A
authors.lastname: Cuneo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D015331:Cohort Studies; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D007376:Interleukin-2 / Q000494:pharmacology; D059785:Karyotype; D007621:Karyotyping / Q000379:methods*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000473:pathology; D008297:Male; D008677:Metaphase / Q000187:drug effects / Q000235:genetics; D008875:Middle Aged; D008934:Mitogens / Q000494:pharmacology; D009841:Oligonucleotides / Q000494:pharmacology; D011379:Prognosis; D016019:Survival Analysis
chemical_list: C539572:CpG-ODN DSP30; D007376:Interleukin-2; D008934:Mitogens; D009841:Oligonucleotides